Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 56
Filtrar
1.
Transplant Proc ; 50(4): 1063-1067, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29731066

RESUMEN

INTRODUCTION: To investigate the correlation between serum anti-ABO immunoglobulin G (IgG) and IgG subclasses, anti-ABO IgG subclasses were measured by flow cytometry (FCM) in ABO-incompatible (ABOi) kidney transplant recipients. We also evaluated baseline anti-ABO C1q antibody. METHOD: Baseline anti-ABO IgG titers were measured by both FCM and column agglutination technique methods in 18 ABOi kidney transplant recipients. The mean florescence intensity (MFI) ratios of baseline anti-ABO IgG subclasses and anti-ABO C1q antibody were obtained by FCM and followed-up after rituximab treatment, each plasmapheresis (PP) session, and kidney transplantation. Correlation between the values of IgG subclass and total IgG titer was analyzed. RESULTS: The baseline MFI ratios of total IgG, IgG1, IgG2, IgG3, and IgG4 were 202.46, 62.41, 30.01, 1.04, and 1.13, respectively. The MFI ratios of IgG1, IgG2, and total IgG measured at baseline and pre-PP were positively correlated with the baseline ABO titer was measured using the column agglutination technique. The numbers of PP sessions to reach the target titer were correlated with the baseline IgG and IgG1 levels. IgG1 and IgG2 as well as total IgG were removed effectively after serial PP. Anti-ABO C1q antibody was neither detected nor correlated with total IgG and any IgG subclasses. CONCLUSIONS: Our findings suggest that IgG1 and IgG2 are the dominant IgG subclass in ABOi kidney transplant recipients. Baseline levels of IgG1 and IgG2 were correlated with baseline total IgG titer. However, anti-ABO C1q antibody was not detected in the present study.


Asunto(s)
Incompatibilidad de Grupos Sanguíneos/inmunología , Inmunoglobulina G/inmunología , Trasplante de Riñón , Antígenos de Grupos Sanguíneos/inmunología , Complemento C1q/inmunología , Desensibilización Inmunológica , Femenino , Citometría de Flujo , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Humanos , Factores Inmunológicos/uso terapéutico , Masculino , Metilprednisolona/uso terapéutico , Ácido Micofenólico/uso terapéutico , Plasmaféresis , Rituximab/uso terapéutico , Tacrolimus/uso terapéutico
2.
Transplant Proc ; 49(5): 1005-1011, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28583516

RESUMEN

BACKGROUND: The recent progress and appropriate use of immunosuppressive drugs have considerably improved the short-term survival in kidney transplantation recipients (KTRs). The development of new strategies to improve long-term survival outcome after kidney transplantation is also becoming important. Although current diagnosis of allograft dysfunction relies on serum creatinine concentration and biopsy, they are nonspecific indicators of allograft function. Therefore, noninvasive, sensitive, and specific biomarkers for the prediction of long-term survival are needed. The aim of this study was to discover potential biomarkers for long-term survival in KTRs through the use of liquid chromatography-tandem mass spectrometry. METHODS: We used the metabolic approach to explore the change of metabolites in the serum of KTRs. Twenty-four KTRs with long-term good survival (LGS) and 10 KTRs with chronic antibody-mediated rejection (CAMR) were included in this study. After quantile normalization with chromatographic data, multivariate statistical analysis was performed. We attempted to analyze metabolic profiling with LGS and CAMR groups. RESULTS: The orthogonal partial least-squares discriminant analysis score plot showed a separation between 2 groups in the principal component. In the corresponding loading plot, 344 metabolites responsible for the separation observed in the score plot were identified (variable influence on projection ≥1.0). We then selected 54 metabolites to compare mass with charge by searching a web database, and 11 compounds were identified. CONCLUSIONS: We found metabolites in serum that differ in LGS and CAMR groups. Further studies are needed to figure out potential metabolomic biomarkers to predict long-term survival in KTRs.


Asunto(s)
Biomarcadores/sangre , Rechazo de Injerto/sangre , Trasplante de Riñón/mortalidad , Metabolómica/métodos , Análisis Discriminante , Humanos , Trasplante Homólogo
3.
Transplant Proc ; 49(5): 1018-1022, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28583518

RESUMEN

BACKGROUND: Precise monitoring of the glomerular filtration rate (GFR) is needed to estimate the allograft function in kidney transplant recipients (KTRs). The GFR is widely estimated with the use of formulas based on serum cystatin C (SCys) and serum creatinine (SCr) levels. We compared the efficacy of SCys-based equations with that of SCr-based equations to predict the allograft function. METHODS: We calculated the Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Cr), CKD-EPI creatinine-cystatin C (CKD-EPI Cr/Cys), and CKD-EPI cystatin C (CKD-EP ICys) equations in 70 KTRs. The measured GFR (mGFR) was defined as the GFR estimated by technetium-99m-diethylene triamine pentaacetic acid (99mTc-DTPA) clearance. The accuracy and precision of the equations were compared with the mGFR. The performance characteristics of SCr and SCys were analyzed with the use of receiver operating characteristic (ROC) curves to ascertain the sensitivity and specificity at the cutoff value of <45 mL/min/1.73 m2 DTPA. RESULTS: Overall, MDRD and CKD-EPICys did not show significant differences from mGFR (P = .05 and P = .077, respectively), whereas CKD-EPI Cr and CKD-EPI Cr/Cys significantly underestimated mGFR (P < .001 and P = .005, respectively). In the subgroup of patients with mGFR <45 mL/min/1.73 m2, CKD-EPI Cys showed little bias (P = .122), whereas MDRD significantly underestimated mGFR (P = .037). The area under the ROC curve for predicting mGFR <45 mL/min/1.73 m2 was 0.80 for SCys, which was better than that for SCr at 0.763. CONCLUSIONS: Cystatin C-based equations showed better predictive performance of the allograft function than creatinine-based equations for the KTRs, including patients with lower GFR. Cystatin C level might be a good alternate measurement to monitor the allograft function.


Asunto(s)
Cistatina C/sangre , Tasa de Filtración Glomerular/fisiología , Pruebas de Función Renal/métodos , Trasplante de Riñón , Adulto , Anciano , Creatinina/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Curva ROC , Insuficiencia Renal Crónica/sangre , Sensibilidad y Especificidad
4.
Transplant Proc ; 49(5): 1038-1042, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28583522

RESUMEN

BACKGROUND: A higher body mass index (BMI) before kidney transplantation (KT) is associated with increased mortality and allograft loss in kidney transplant recipients (KTRs). However, the effect of changes in BMI after KT on these outcomes remains uncertain. The aim of this study was to investigate the effect of baseline BMI and changes in BMI on clinical outcomes in KTRs. METHODS: A total of 869 KTRs were enrolled from a multicenter observational cohort study from 2012 to 2015. Patients were divided into low and high BMI groups before KT based on a BMI cutoff point of 23 kg/m2. Differences in acute rejection and cardiovascular disease (CVD) between the 2 groups were analyzed. In addition, clinical outcomes across the 4 BMI groups divided by BMI change 1 year after KT were compared. Associations between BMI change and laboratory findings were also evaluated. RESULTS: Patients with a higher BMI before KT showed significantly increased CVD after KT (P = .027) compared with patients with a lower BMI. However, among the KTRs with a higher baseline BMI, only persistently higher BMI was associated with increased CVD during the follow-up period (P = .003). Patients with persistently higher BMI had significantly decreased high-density lipoprotein cholesterol and increased hemoglobin, triglyceride, and hemoglobin A1c levels. Baseline BMI and post-transplantation change in BMI were not related to acute rejection in KTRs. CONCLUSIONS: BMI in the 1st year after KT as well as baseline BMI were associated with CVD in KTRs. More careful monitoring of obese KTRs who do not undergo a reduction in BMI after KT is required.


Asunto(s)
Índice de Masa Corporal , Enfermedades Cardiovasculares/fisiopatología , Rechazo de Injerto/fisiopatología , Trasplante de Riñón/mortalidad , Adulto , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/mortalidad , Estudios de Cohortes , Femenino , Hemoglobina Glucada/análisis , Rechazo de Injerto/sangre , Rechazo de Injerto/mortalidad , Humanos , Lipoproteínas HDL/sangre , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Factores de Riesgo , Factores de Tiempo , Triglicéridos/sangre
5.
Oral Dis ; 23(1): 102-109, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27614106

RESUMEN

OBJECTIVES: Our study aims to identify genetic variants associated with hereditary gingival fibromatosis (HGF) by applying whole-exome sequencing (WES) and bioinformatics analyses such as gene set enrichment analysis (GSEA) and protein functional network study. SUBJECTS AND METHODS: Two affected siblings whose grandparents and parents have normal gingiva were chosen for our investigation. Saliva collected from the patients and their parents were used for WES. GSEA and protein functional network study were performed to find gene groups in a biological coordination which are associated with HGF. RESULTS: Genetic variants for homozygotes and compound heterozygotes were analyzed and translated into 845 genes. The result from protein functional network study showed that these genetic variants were mainly observed in genes affecting fibronectin as well as the immune and autoimmune system. Additionally, three mutated genes in our HGF patients, TMCO1, RIN2, and INSR, were found through human phenotype ontology (HPO) to have potential to contribute to gingival hyperplasia. CONCLUSIONS: Genetic analysis of HGF in this study implicated mutations in fibronectin and the immune system as triggering abnormal gingival fibromatosis.


Asunto(s)
Exoma/genética , Fibromatosis Gingival/genética , Adolescente , Antígenos CD/genética , Canales de Calcio , Proteínas Portadoras/genética , Niño , Femenino , Predisposición Genética a la Enfermedad/genética , Variación Genética/genética , Genoma/genética , Factores de Intercambio de Guanina Nucleótido/genética , Humanos , Masculino , Proteínas de la Membrana/genética , Linaje , Receptor de Insulina/genética , Alineación de Secuencia , Análisis de Secuencia de ADN
6.
Transplant Proc ; 47(3): 591-5, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25891693

RESUMEN

BACKGROUND: The aim of this study was to compare anti-ABO antibody levels as measured by means of flow cytometry (FCM) with the levels measured with the use of the column agglutination test (CAT), and to evaluate the clinical outcome as it relates to the baseline mean fluorescence intensity (MFI) ratio obtained by FCM. METHODS: We reviewed 21 cases of ABO-incompatible kidney transplantation (ABO-i KT). In these patients, baseline IgG titers were measured with the use of both FCM and CAT methods. We investigated the correlation between levels measured by FCM and those by CAT with the use of correlation coefficients. Patients were classified into a high MFI ratio group (≥200; n = 7) or low MFI ratio group (<200; n = 14). RESULTS: The MFI ratio for the FCM-based method was highly correlated with the titer measured by CAT (r = 0.890; P = .01). The relationship between MFI ratio and CAT titer can be expressed as follows: log (MFI ratio) = 0.879 × log (CAT titer) + 0.298. The number of pre-transplantation rounds of plasmapheresis significantly increased as the baseline MFI ratio increased. The allograft function was immediately recovered and stable. A single case of acute cellular rejection was observed in the low MFI ratio group. CONCLUSIONS: Anti-ABO antibody levels measured by means of the FCM-based method were highly correlated with the levels measured with the use of CAT in cases of ABO-i KT. The decreased level of anti-ABO antibody measured by means of FCM after plasmapheresis suggests its potential as an effective and objective method for assessment of anti-ABO antibody levels.


Asunto(s)
Sistema del Grupo Sanguíneo ABO/inmunología , Anticuerpos/sangre , Incompatibilidad de Grupos Sanguíneos/inmunología , Citometría de Flujo/métodos , Trasplante de Riñón , Adulto , Pruebas de Aglutinación/métodos , Femenino , Fluorescencia , Rechazo de Injerto/inmunología , Humanos , Masculino , Persona de Mediana Edad , Plasmaféresis/métodos , Trasplante Homólogo
7.
Transplant Proc ; 47(3): 635-9, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25891701

RESUMEN

BACKGROUND: Human leukocyte antigen (HLA)-A, HLA-B, and HLA-DR matching has beneficial long-term effects on renal allograft survival. However, the gene dosage effect of mismatched HLA on transplant outcomes is not known. We investigated the HLA gene dosage effects on allograft survival in kidney transplant recipients (KTRs). METHODS: We analyzed HLA typing of KTRs and kidney donors at Kyungpook National University Hospital from January 1982 to December 2012. KTRs were divided into 2 groups: recipients from homozygous HLA donors and recipients from heterozygous HLA donors. Death-censored graft survival of KTRs was compared according to allele state of kidney donors. RESULTS: In this study, 697 KTRs were enrolled. According to Kaplan-Meier analysis, graft survival in KTRs of HLA-DR and HLA-B heterozygous donors was longer than that in KTRs of HLA-DR and HLA-B homozygous donors (P = .007 and P < .0001, respectively). Multivariate Cox proportional hazards model analysis showed that HLA-DR and HLA-B donor homozygosity was an independent risk factor for death-censored graft survival (P = .019 and P = .022, respectively). Death-censored graft survival was not associated with HLA-A and HLA-A, B, DR allele states. CONCLUSIONS: Compared with HLA donor mismatch caused by HLA-DR and HLA-B heterozygosity, HLA donor mismatch caused by HLA-DR and HLA-B homozygosity was associated with significantly increased risk of graft failure. In addition to the number of HLA mismatch between KTRs and donors, the donor allele state should be considered to predict transplant outcomes.


Asunto(s)
Dosificación de Gen , Supervivencia de Injerto/inmunología , Antígenos HLA/genética , Trasplante de Riñón , Riñón/inmunología , Adulto , Femenino , Marcadores Genéticos , Supervivencia de Injerto/genética , Heterocigoto , Prueba de Histocompatibilidad , Homocigoto , Humanos , Estimación de Kaplan-Meier , Masculino , Análisis Multivariante , Modelos de Riesgos Proporcionales , Factores de Riesgo , Trasplante Homólogo
8.
Transplant Proc ; 47(3): 660-5, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25891706

RESUMEN

BACKGROUND: The objective of this study was to investigate the clinical impact of BK virus surveillance on graft injury in kidney transplantation. METHODS: BK viremia in kidney transplant recipients was evaluated by use of plasma quantitative polymerase chain reaction. The prevalence of BK viremia and BK virus-associated nephropathy (BKVAN) and the clinical impact of BK viremia on graft outcomes were assessed. RESULTS: This study took place between January 2008 and June 2013. A total of 213 kidney transplant recipients were included. The prevalence of BK viremia and high BK viremia (≥1 × 10(4) copies/mL) was 66.7% (142/213) and 17.4% (37/213), respectively. A diagnosis of BKVAN was confirmed by means of allograft biopsy in 9 patients (4.2%). The estimated glomerular filtration rate after transplantation was similar in both the low BK viremia (<1 × 10(4) copies/mL) and non-BK viremia groups but was significantly lower in the high BK viremia group after 18 months. In receiver operating characteristic curve analysis, the area under the curve value of plasma polymerase chain reaction was 0.980. We found that a viral load >92,850 copies/mL was able to predict BKVAN with 89% sensitivity and 94.6% specificity. The risk factors for viral loads ≥1 × 10(4) copies/mL were cytomegalovirus infection, steroid pulse therapy, and acute rejection. CONCLUSIONS: High BK viremia was associated with poor graft function after kidney transplantation. The serial monitoring of BK viremia in kidney transplant recipients was helpful in predicting BKVAN and might prevent further progression.


Asunto(s)
Virus BK/aislamiento & purificación , Trasplante de Riñón , Infecciones por Polyomavirus/diagnóstico , Complicaciones Posoperatorias/diagnóstico , Infecciones Tumorales por Virus/diagnóstico , Viremia/diagnóstico , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Infecciones por Polyomavirus/epidemiología , Infecciones por Polyomavirus/etiología , Complicaciones Posoperatorias/epidemiología , Prevalencia , Curva ROC , Sensibilidad y Especificidad , Trasplante Homólogo , Infecciones Tumorales por Virus/epidemiología , Infecciones Tumorales por Virus/etiología , Viremia/epidemiología , Viremia/etiología
9.
Transplant Proc ; 47(3): 666-71, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25891707

RESUMEN

BACKGROUND: Hyperglycemia occurs frequently after kidney transplantation and may be reversed when the dosage of the immunosuppressive agents is tapered. However, the effect of transient post-transplantation hyperglycemia (PTH) on transplantation outcomes is not well described. METHODS: Kidney transplant recipients without diabetes who underwent kidney transplantation between 2001 and 2012 were enrolled in the study. Transient PTH was defined as recovery from PTH without further antidiabetic therapy and the maintenance of glycated hemoglobin levels <6.5% at 1 year after transplantation. Persistent PTH until 1 year after transplantation was considered to be new-onset diabetes after transplantation (NODAT). The factors associated with increased risk of PTH were analyzed. We compared the development of diabetes mellitus, cardiovascular disease, and other transplantation outcomes among patients with no PTH, transient PTH, and NODAT. RESULTS: Among 176 kidney transplant recipients, 106 (60.2%) developed PTH and 58 (54.7%) of 106 patients with PTH had transient PTH. Older age, high body mass index (BMI), and female gender were independent risk factors for transient PTH. The incidence of diabetes was not significantly different between patients with no PTH and those with transient PTH. The incidence of cardiovascular disease was significantly increased in NODAT group compared with that in no PTH and transient PTH groups. However, the incidences of acute rejection, allograft loss, and patient death were comparable among the three groups. CONCLUSIONS: Transient hyperglycemia after kidney transplantation was found to be associated with older age, high body mass index, and female gender. Transient elevation of blood glucose level did not affect post-transplantation outcomes, including diabetes mellitus and cardiovascular disease. However, patients with NODAT should be carefully monitored for the occurrence of cardiovascular disease.


Asunto(s)
Enfermedades Cardiovasculares/etiología , Diabetes Mellitus/etiología , Hiperglucemia/etiología , Trasplante de Riñón , Complicaciones Posoperatorias/etiología , Adulto , Anciano , Enfermedades Cardiovasculares/epidemiología , Diabetes Mellitus/epidemiología , Femenino , Humanos , Hiperglucemia/epidemiología , Hiperglucemia/fisiopatología , Incidencia , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Factores de Riesgo
10.
Transpl Infect Dis ; 16(6): 993-8, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25251070

RESUMEN

Rhabdomyolysis is a pathological syndrome caused by skeletal muscle cell damage that affects the integrity of the cellular membrane and leads to the release of toxic intracellular constituents into the bloodstream. Although cytomegalovirus (CMV) has rarely been reported as a cause of rhabdomyolysis, CMV infection could be considered as a possible cause because of its clinical significance in kidney transplant recipients (KTRs). We report 2 cases of rhabdomyolysis associated with CMV infection in KTRs. A 64-year-old woman (Case 1) and a 65-year-old man (Case 2), who had each received a kidney from a living unrelated donor, were admitted with complaints of weakness in both legs and myalgia. Laboratory findings revealed highly increased creatine phosphokinase and myoglobinuria. In both cases, no recent alterations of medications had occurred, and other causes of rhabdomyolysis--such as trauma, alcohol, drugs, and electrolyte abnormalities - were excluded. CMV pp65 antigen was positive, and patients were diagnosed with rhabdomyolysis associated with CMV infection. Both patients recovered without complications after ganciclovir treatment. In conclusion, CMV infection should be considered as a possible cause of rhabdomyolysis in KTRs.


Asunto(s)
Infecciones por Citomegalovirus/complicaciones , Trasplante de Riñón/efectos adversos , Rabdomiólisis/etiología , Anticuerpos Antivirales/sangre , Antivirales/uso terapéutico , Infecciones por Citomegalovirus/tratamiento farmacológico , Femenino , Ganciclovir/uso terapéutico , Humanos , Inmunoglobulina G/sangre , Masculino , Persona de Mediana Edad
11.
Transpl Infect Dis ; 16(2): 295-303, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24628837

RESUMEN

BACKGROUND: The optimal duration of antiviral therapy for kidney transplant recipients (KTR) with chronic hepatitis B virus (HBV) infection remains unclear. We reported the long-term outcomes after withdrawal of antiviral agent in KTR with chronic HBV infection. METHODS: We retrospectively investigated the hepatitis B surface antigen (HBsAg)-positive KTR with antiviral agents between January 2002 and January 2012. Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months. All patients were followed regularly at approximately 3-6 months for liver enzyme, viral markers, and HBV DNA level after antiviral withdrawal. RESULTS: Among a total of 445 KTR, 14 HBsAg-positive patients were included in this study. Antiviral agents were used, with lamivudine in 11 patients, and with adefovir, entecavir, and telbivudine in 3 patients, respectively. Discontinuation of antiviral agent was attempted in 6 (42.9%) of 14 patients who satisfied the criteria. The median duration of antiviral therapy before withdrawal was 14.3 months (range, 9-24 months). Four (66.7%) of 6 patients were successfully withdrawn and remained negative for HBV DNA for a median 60.5 months (range, 47-82 months). The baseline HBV DNA level was not related to maintenance of remission after withdrawal. Two reactivated patients resumed antiviral treatment immediately, with subsequent normalization of HBV DNA. During the follow-up, 1 patient developed hepatocellular carcinoma; however, no patient death or graft failure was reported for all HBsAg-positive KTR. CONCLUSIONS: Antiviral therapy can be discontinued successfully and safely in selected KTR with chronic HBV infection, after complete suppression of HBV and sufficient duration of antiviral therapy.


Asunto(s)
Antivirales/uso terapéutico , ADN Viral/sangre , Virus de la Hepatitis B/fisiología , Hepatitis B Crónica/tratamiento farmacológico , Trasplante de Riñón , Privación de Tratamiento , Adenina/análogos & derivados , Adenina/uso terapéutico , Adulto , Alanina Transaminasa/sangre , Femenino , Estudios de Seguimiento , Guanina/análogos & derivados , Guanina/uso terapéutico , Antígenos de Superficie de la Hepatitis B/sangre , Antígenos e de la Hepatitis B/sangre , Virus de la Hepatitis B/inmunología , Hepatitis B Crónica/sangre , Humanos , Inmunosupresores/administración & dosificación , Lamivudine/uso terapéutico , Masculino , Persona de Mediana Edad , Organofosfonatos/uso terapéutico , Estudios Retrospectivos , Telbivudina , Timidina/análogos & derivados , Timidina/uso terapéutico , Factores de Tiempo , Activación Viral
12.
Transplant Proc ; 45(8): 2899-902, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-24157000

RESUMEN

INTRODUCTION: Screening for latent tuberculosis infection (LTBI) before kidney transplantation (KT) is an indispensable process, purposes of this study were to compare the QuantiFERON-TB Gold In-Tube test (QFT-GIT) with the tuberculin skin test (TST) for screening of LTBI in kidney transplant recipients (KTRs). METHODS: We compared prospectively the results of QFT-GIT with TST in 97 KTRs screened for LTBI between July 2008 and July 2012. Isoniazid (INH) prophylaxis was applied to KTRs with a positive TST or positive QFT-GIT or clinical risk factors for LTBI. Post-transplant tuberculosis (TB) was diagnosed by clinical evidence. RESULTS: The mean patients follow-up was 24.6 ± 14.4 months. Positive results on QFT-GIT and TST was obtained among 19 (20.4%) and 12 (12.9%) subjects, respectively, an overall agreement of 79.3% (κ = 0.27, 95% confidence interval [CI] -0.03-0.50; P < .014). The incidence of TB was 0.52 per 100 person-years (95% CI 0.02-3.68). None of the patients in the INH prophylaxis group developed TB, whereas 1 in the no prophylaxis group developed disease at 14 months after KT. Sensitivity of the 2 tests could not be compared because patients who showed positive results on QFT-GIT or TST did not develop TB. The difference of specificity between QFT-GIT (79.3%) and TST (86.9%) was not significant (P = .l67). Abnormal chest radiographs (odds ratio [OR] 27.94, 95% CI 1.22-636.61, P = .037) and positive TST (OR 7.65, 95% CI 1.75-33.30, P = .007) showed significant associations with positive QFT-GIT results. Only positive QFT-GIT (OR 6.03, 95% CI 1.51-24.01, P = .011) showed an association with positive TST results. CONCLUSIONS: QFT-GIT and TST for diagnosis of LTBI in KTRs showed reasonable concordance but no superiority of either test.


Asunto(s)
Trasplante de Riñón , Tuberculosis Latente/diagnóstico , Prueba de Tuberculina , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sensibilidad y Especificidad
13.
Transplant Proc ; 45(4): 1487-90, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23726603

RESUMEN

BACKGROUND: Mycophenolate mofetil (MMF) has been used worldwide as part of maintenance immunosuppression since initial large cyclosporine-based trials reported that compared with azathioprine (AZA), MMF reduced acute rejection episodes after renal transplantation. However, long-term benefits of MMF have not been established; the follow-up period of previous studies was within 5 years. The aim of this study was to compare the acute rejection rates, allograft function, and graft and patient survivals of these 2 drugs in conjunction with cyclosporine and steroids over a period of 10 years. METHODS: We reviewed recipients who had undergone kidney transplantation from January 1998 to January 2002. Eighty-six patients were divided into 2 groups (MMF = 43, AZA = 43). All patients received cyclosporine and steroids concomitantly as maintenance immunosuppressive therapy. RESULTS: Baseline characteristics were similar between the 2 groups except donor type. Multiple logistic regression analysis showed MMF therapy to reduce the acute rejection rate in the first 12 months after transplantation (relative risk [RR], 0.181; 95% confidence interval [CI], 0.035-0.936; P = .042). Cox proportional hazard analysis revealed MMF to was not associated with improved graft and patient survival. Graft function was comparable between the 2 groups over 10 years. No significant differences were observed in the incidence of serious infections or malignancy. CONCLUSIONS: Compared with AZA, MMF offered the clinical benefit of prevention of acute rejection episodes, but displayed similar effects on long-term graft and patient survivals in kidney transplant recipients undergoing cyclosporine-based immunosuppression.


Asunto(s)
Azatioprina/administración & dosificación , Ciclosporina/administración & dosificación , Inmunosupresores/administración & dosificación , Trasplante de Riñón , Ácido Micofenólico/análogos & derivados , Adulto , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ácido Micofenólico/administración & dosificación
14.
Transplant Proc ; 45(4): 1584-9, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23726625

RESUMEN

BACKGROUND: Urinary tract infections (UTIs) are the most common infectious complication in kidney transplant recipients (KTRs). The aim of this study to investigate the risk factors for and causative organisms of UTI as well as to evaluate the impact these diseases on allograft function in KTRs. METHODS: We analyzed patients who underwent kidney transplantation (KT) between January 2000 and December 2010. Among a total of 344 KTRs, 50 (14.5%) patients experienced 106 UTI episodes during a mean follow-up of 35.9 ± 26.0 months. Twenty three patients experiencing recurrent UTI were compared with 27 nonrecurrent UTI patients and with 50 non-UTI patients matched for age, gender, and transplantation date. RESULTS: The number of patients with renal calculi, diabetes, or prior dialysis was significantly greater among the UTI group compared with control subjects. In addition, the number of patients with renal calculi was significantly higher among the recurrent compared with the nonrecurrent cohort (43.5 vs 7.4%; P = .003). The most common causative organism was Escherichia coli (64.1%), followed by Enterococcus species (20.5%). Higher rates of antibiotic resistance, especially Extended Spectrum Beta-Lactamasc (ESBL) production, were observed among the recurrent compared with the nonrecurrent group (53.1 vs 0%; P = .013). The rate of decline of estimated glomerular filtration rate was significantly faster in the UTI than the non-UTI group, whereas it did not differ between the recurrent and nonrecurrent group. CONCLUSIONS: Adequate treatment of an initial UTI to prevent as recurrent infection and prolong graft longevity is especially reasonable for KTRs with renal calculi or in cases of antibiotic-resistant microorganisms.


Asunto(s)
Trasplante de Riñón , Infecciones Urinarias/epidemiología , Adulto , Creatinina/sangre , Femenino , Humanos , Masculino , Recurrencia , Estudios Retrospectivos , Factores de Riesgo , Infecciones Urinarias/microbiología
15.
Cell Death Differ ; 20(8): 1055-67, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23645206

RESUMEN

ZNF313 encoding a zinc-binding protein is located at chromosome 20q13.13, which exhibits a frequent genomic amplification in multiple human cancers. However, the biological function of ZNF313 remains largely undefined. Here we report that ZNF313 is an ubiquitin E3 ligase that has a critical role in the regulation of cell cycle progression, differentiation and senescence. In this study, ZNF313 is initially identified as a XIAP-associated factor 1 (XAF1)-interacting protein, which upregulates the stability and proapoptotic effect of XAF1. Intriguingly, we found that ZNF313 activates cell cycle progression and suppresses cellular senescence through the RING domain-mediated degradation of p21(WAF1). ZNF313 ubiquitinates p21(WAF1) and also destabilizes p27(KIP1) and p57(KIP2), three members of the CDK-interacting protein (CIP)/kinase inhibitor protein (KIP) family of cyclin-dependent kinase inhibitors, whereas it does not affect the stability of the inhibitor of CDK (INK4) family members, such as p16(INK4A) and p15(INK4B). ZNF313 expression is tightly controlled during the cell cycle and its elevation at the late G1 phase is crucial for the G1-to-S phase transition. ZNF313 is induced by mitogenic growth factors and its blockade profoundly delays cell cycle progression and accelerates p21(WAF1)-mediated senescence. Both replicative and stress-induced senescence are accompanied with ZNF313 reduction. ZNF313 is downregulated during cellular differentiation process in vitro and in vivo, while it is commonly upregulated in many types of cancer cells. ZNF313 shows both the nuclear and cytoplasmic localization in epithelial cells of normal tissues, but exhibits an intense cytoplasmic distribution in carcinoma cells of tumor tissues. Collectively, ZNF313 is a novel E3 ligase for p21(WAF1), whose alteration might be implicated in the pathogenesis of several human diseases, including cancers.


Asunto(s)
Proteínas Portadoras/fisiología , Puntos de Control del Ciclo Celular/fisiología , Senescencia Celular/fisiología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/fisiología , Factores de Transcripción/fisiología , Ubiquitina-Proteína Ligasas/fisiología , Proteínas Adaptadoras Transductoras de Señales , Animales , Apoptosis/fisiología , Proteínas Reguladoras de la Apoptosis , Ciclo Celular/fisiología , Diferenciación Celular/fisiología , Línea Celular , Línea Celular Tumoral , Proteínas F-Box/fisiología , Xenoinjertos , Humanos , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intracelular/fisiología , Masculino , Ratones , Ratones Desnudos , Modelos Animales , Proteínas de Neoplasias/fisiología
16.
Transpl Infect Dis ; 14(5): E50-5, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22823928

RESUMEN

Mycobacterium kansasii is the second most common non-tuberculous mycobacteria in kidney transplant recipients (KTRs) and has been reported to cause disseminated infection in KTRs. We report the first case to our knowledge of M. kansasii pericarditis after kidney transplantation in a 54-year-old man. The patient was admitted with a 2-month history of intermittent fever and myalgia, treated with oral prednisolone and mycophenolate mofetil prior to admission. Chest computed tomography showed enlarged mediastinal lymph node and small amount of pericardial effusion. Mediastinoscopic biopsy of mediastinal lymph node revealed reactive hyperplasia, without evidence of granuloma, but acid-fast bacilli stain of pericardial fluid reported positive finding and pericardial fluid culture identified M. kansasii. The patient has been treated successfully with rifabutin-based combination therapy. All available cases of M. kansasii infection in kidney transplant patients and M. kansasii pericarditis in human immunodeficiency virus-infected patients are comprehensively reviewed.


Asunto(s)
Trasplante de Riñón/efectos adversos , Infecciones por Mycobacterium no Tuberculosas/microbiología , Mycobacterium kansasii/aislamiento & purificación , Pericarditis/microbiología , Antibacterianos/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Pericarditis/tratamiento farmacológico , Rifabutina/uso terapéutico
17.
Transplant Proc ; 44(1): 109-14, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22310591

RESUMEN

BACKGROUND: Tacrolimus is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp), encoded by the CYP3A and ATP-binding cassette subfamily B member 1 (ABCB1) genes, respectively. This study was aimed to investigate the impact of CYP3A and ABCB1 polymorphisms on the tacrolimus pharmacokinetics and clinical outcomes in Korean renal transplant recipients. METHODS: We analyzed data from a cohort of 70 renal transplant recipients receiving tacrolimus. CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A5*3, ABCB1 C1236>T, ABCB1 G2677>T/A, and ABCB1 C3435>T polymorphisms were genotyped and correlated to dose-adjusted tacrolimus trough concentration at months 1, 3, 6, and 12 after transplantation. RESULTS: Patients with the CYP3A5*3 alleles showed higher dose-adjusted tacrolimus concentrations for 12 months and higher trough levels until 6 months after transplantation. ABCB1 polymorphisms and haplotypes were not associated with tacrolimus concentrations. In a multivariate analysis, the presence of ≥1 CYP3A5*3 allele was a significant independent variable affecting dose-adjusted tacrolimus concentrations. Glomerular filtration rate, acute rejection, opportunistic infection, and graft survival were not affected by CYP3A5 polymorphisms. Calcineurin inhibitor toxicity, which showed higher tendency in patients with CYP3A5*1 alleles, might be associated with higher tacrolimus dose per kilogram. CONCLUSIONS: The CYP3A5 genotype is a major factor in determining the dose requirement of tacrolimus, and genotyping may be of value in individualization of immunosuppressive therapy of renal transplant patients.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Pueblo Asiatico/genética , Citocromo P-450 CYP3A/metabolismo , Inmunosupresores/farmacocinética , Trasplante de Riñón , Polimorfismo de Nucleótido Simple , Tacrolimus/farmacocinética , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Adulto , Anciano , Distribución de Chi-Cuadrado , Citocromo P-450 CYP3A/genética , Monitoreo de Drogas , Femenino , Frecuencia de los Genes , Tasa de Filtración Glomerular/efectos de los fármacos , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/efectos de los fármacos , Haplotipos , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Estimación de Kaplan-Meier , Enfermedades Renales/inducido químicamente , Trasplante de Riñón/etnología , Trasplante de Riñón/inmunología , Modelos Lineales , Desequilibrio de Ligamiento , Modelos Logísticos , Masculino , Persona de Mediana Edad , Fenotipo , República de Corea/epidemiología , Medición de Riesgo , Factores de Riesgo , Tacrolimus/administración & dosificación , Tacrolimus/efectos adversos , Resultado del Tratamiento , Adulto Joven
18.
Transplant Proc ; 44(1): 200-3, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22310614

RESUMEN

BACKGROUND: For many highly allosensitized renal transplant candidates, an acceptable donor is never identified, and the patient remains on dialysis indefinitely. In an attempt to ameliorate this situation, several desensitization protocols have been developed that permit positive-crossmatch kidney transplantation. Here, we report our experiences of living donor kidney transplantation in highly sensitized patients. METHODS: We treated seven highly sensitized patients between March 2003 and September 2009. All patients underwent desensitization using pretransplant plasmapheresis (PP) and low-dose intravenous immunoglobulin (IVIG; 100 mg/kg) with rituximab (six patients) or without rituximab (one patient). Demographics, immunologic characteristics of patients, allograft function, acute rejection (AR) episodes, survival, and adverse events were evaluated. RESULTS: Seven patients with positive-crossmatch tests or high levels of panel-reactive antibody (PRA) were included. Their mean age was 51.4 ± 3.3 years. The average number of human leukocyte antigen mismatchs was 3.4 ± 0.5. The mean percent PRA was 41.7% ± 6.1%. Six patients were crossmatch-positive, and one patient was crossmatch-negative but had high PRA levels. The mean follow-up period was 33.2 ± 5.4 months after transplantation. The all patients showed no AR episodes for follow-up period, and the patient and graft survival rates were 100%. The mean serum creatinine concentration at last follow-up was 0.92 ± 0.11 mg/dL. CONCLUSIONS: Our experiences suggest that the combination of PP and low-dose IVIG with or without rituximab may prove effective as a desensitization regimen for positive-crossmatch and/or highly sensitized living donor renal transplant recipients. Further investigations are needed to evaluate the long-term clinical efficacy and safety of this approach.


Asunto(s)
Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Desensibilización Inmunológica/métodos , Histocompatibilidad , Inmunoglobulinas Intravenosas/administración & dosificación , Inmunosupresores/administración & dosificación , Trasplante de Riñón/inmunología , Plasmaféresis , Adulto , Anciano , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Biomarcadores/sangre , Creatinina/sangre , Desensibilización Inmunológica/efectos adversos , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto , Antígenos HLA/inmunología , Prueba de Histocompatibilidad , Humanos , Inmunoglobulinas Intravenosas/efectos adversos , Inmunosupresores/efectos adversos , Isoanticuerpos/sangre , Donadores Vivos , Persona de Mediana Edad , Plasmaféresis/efectos adversos , República de Corea , Rituximab , Factores de Tiempo , Resultado del Tratamiento
19.
Perfusion ; 26(6): 524-8, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21844113

RESUMEN

BACKGROUND: Insufflation of carbon dioxide (CO(2)) to the operative field has been used to prevent major organ injury attributed to air embolisms in cardiac surgery. However, it may be preferable to avoid hypercapnia induced by CO(2) insufflation, owing to its potentially harmful effect. To investigate the effectiveness of near-infrared spectroscopy (NIRS) as a possible method for continuous monitoring of arterial CO(2) tension during cardiac surgery, we evaluated the correlation between the change in arterial CO(2) tension and the change in regional cerebral oxygen saturation (rScO(2)) obtained from NIRS in as controlled a condition as possible. METHODS: Thirty patients who underwent surgical correction for atrial or ventricular septal defects were enrolled in this study. Patients who had pulmonary hypertension or other intracardiac anomalies were excluded. Anesthetic and cardiopulmonary bypass (CPB) management were conducted according to our standard institutional practice. Data obtained from arterial blood gas analyses and corresponding regional cerebral oxygen saturation (rScO(2)) recorded from NIRS before and after the insufflations of CO(2) during CPB were used for analysis. RESULTS: The change in arterial CO(2) tension correlated with the change in rScO(2) in the left hemisphere (r = 0.681, p <0.001, y = -1.393 + 0.547x) and right hemisphere (r = 0.690, p <0.001, y = -1.999 + 0.486x). To control the effects of other variables, including hematocrit and temperature, these relationship were not reduced (left hemisphere: r=0.678, p<0.001; right hemisphere: r=0.634, p<0.001). CONCLUSIONS: Since the change in regional cerebral oxygen saturation was correlated with the change in arterial CO(2) tension during mild hypothermic CPB, NIRS might be a possible non-invasive method for monitoring of arterial CO(2) tension without incurring additional cost in this setting.


Asunto(s)
Dióxido de Carbono/sangre , Puente Cardiopulmonar/métodos , Espectroscopía Infrarroja Corta/métodos , Adolescente , Adulto , Temperatura Corporal , Procedimientos Quirúrgicos Cardíacos/métodos , Ventrículos Cerebrales/irrigación sanguínea , Ventrículos Cerebrales/metabolismo , Niño , Preescolar , Femenino , Atrios Cardíacos/cirugía , Ventrículos Cardíacos/cirugía , Hematócrito , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
20.
Tissue Antigens ; 76(4): 289-96, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20545903

RESUMEN

Several studies have showed an association of gene polymorphisms with the development of glomerulonephritis (GN). We investigated the effects of gene polymorphisms on the development of GN by analyzing polymorphisms in the interleukin (IL)-18, transforming growth factor (TGF)-ß, and vascular endothelial growth factor (VEGF) genes in Korean patients with primary GN. The study included 146 normal subjects (controls) and 100 patients diagnosed with primary GN by kidney biopsy. The gene polymorphisms A-607C and G-137C in IL-18, C-509T and T869C in TGF-ß1, and C-2578A and C405G in VEGF were investigated in DNA extracted from peripheral blood. Significant differences were observed between the GN and control groups in the genotype and allele frequencies of A-607C IL-18 and C405G VEGF. The frequencies of the IL-18-607CC genotype [P = 0.001, odds ratio (OR) = 2.473] and the VEGF 405GG genotype (P = 0.001, OR = 2.473) were significantly increased in the GN group. The combination of IL-18-607CC+ and VEGF 405GG+ genotypes had a higher risk for developing GN in comparison with the combination of IL-18-607CC- and VEGF 405GG- genotypes (P < 0.001, OR = 8.642). In the haplotype analysis of the IL-18 gene, the CG haplotype was significantly more frequent in the GN group than the control group (61.5% vs 46.9%, P = 0.002). These results show that the -607CC genotype of the IL-18 gene and the 405GG genotype of the VEGF gene are associated with susceptibility to and the development of primary GN.


Asunto(s)
Glomerulonefritis/genética , Interleucina-18/genética , Polimorfismo Genético , Factor de Crecimiento Transformador beta/genética , Factores de Crecimiento Endotelial Vascular/genética , Adulto , Pueblo Asiatico/genética , Femenino , Predisposición Genética a la Enfermedad , Haplotipos , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA